Nilotinib Torrent

Nilotinib, the active ingredient in Nilotinib Torrent, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats Philadelphia chromosome‑positive chronic myeloid leukemia and acute lymphoblastic leukemia in adult patients.

GNH USA supplies Nilotinib Torrent as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Nilotinib is a targeted therapy that inhibits BCR‑ABL driven leukemic pathways. It is indicated for the following conditions: - Chronic myeloid leukemia (CML): improves disease control and prolongs survival across chronic, accelerated and blast phases. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): contributes to remission when used in combination regimens. - Accelerated‑phase CML: helps achieve cytogenetic and molecular responses in patients progressing beyond chronic phase.

Nilotinib may cause a range of adverse reactions. Patients should be monitored regularly for both common and serious events.

Common Side Effects: - Nausea - Diarrhea - Rash or skin discoloration - Fatigue - Headache - Arthralgia

Serious or Rare Side Effects: - QT interval prolongation leading to arrhythmia - Pancreatitis - Severe hepatic injury - Grade 3/4 neutropenia - Grade 3/4 thrombocytopenia - Stevens‑Johnson syndrome or toxic epidermal necrolysis

Nilotinib requires careful monitoring and patient education before and during therapy. - Cardiac monitoring: baseline and periodic ECGs to detect QT prolongation. - Hepatic function: assess liver enzymes before initiation and during treatment. - Hematologic surveillance: regular complete blood counts to identify neutropenia or thrombocytopenia. - Pregnancy risk: contraindicated in pregnancy (Category D); advise effective contraception. - Elderly patients: use with caution due to increased susceptibility to cardiac and metabolic effects. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Nilotinib interacts with several drug classes; clinicians should review concomitant medications.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase nilotinib exposure and toxicity. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy by lowering plasma levels. - Antacids or proton‑pump inhibitors that raise gastric pH: can markedly decrease nilotinib absorption. - Other QT‑prolonging agents (e.g., fluoroquinolones, antiarrhythmics): increase risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates with narrow therapeutic index (e.g., warfarin, certain statins): may require dose adjustment. - Oral contraceptives: reduced effectiveness possible, advise alternative contraception. - Diuretics that affect electrolyte balance: monitor potassium and magnesium levels. - Antifungal azoles with moderate CYP3A4 inhibition (e.g., fluconazole): may modestly raise nilotinib levels.